Full-Time

Senior Director

GMP Operational Quality

Posted on 3/16/2025

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

No salary listed

Senior, Expert

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

This is a hybrid role working 3 days on-site and up to two days remotely.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Risk Management
Requirements
  • Successful strategic leadership experience
  • Successful people development and building/leading high efficiency teams experience
  • In-depth global health regulatory agency knowledge and experience across GxP life cycle in small molecules, devices and combination products preferred
  • Demonstrated strategic planning and execution skills required for operational effectiveness and compliance
  • Broad technical knowledge in across product modalities, different types of processing and testing
  • Current knowledge of industry trends and best practices
  • Excellent communication skills and a proven track record influencing/building/promoting a culture of quality and excellence
  • Ability to apply risk management principles to decision making and operational priorities
  • Critical thinking and problem-solving skills
  • Bachelor’s and Master's degree in a Scientific/Technical/Business discipline
  • 15+ years of experience and 7+ years in a management/supervisory role, or the equivalent combination of education and experience in a regulated pharmaceutical environment
Responsibilities
  • Ensure organization design, resources, capabilities, and processes are built to support the Vertex Small Molecule business needs
  • Responsible for oversight of external quality operations in support of GMP manufacturing (Development and Commercial) activities
  • Quality support of Tech Transfer and Process Validation activities
  • Disposition of batches
  • Responsible for Change Management to ensure proper evaluation of process related changes and to ensure compliance to Regulatory filings
  • Oversight of CDMO performance to compliance and Quality Agreement expectations
  • Establish Quality leadership engagement to deliver on expectations and process performance evaluations
  • Drive Quality operations messaging for Business Review Meetings
  • Drive Continuous Improvement through Operational Review and improvement initiatives
  • Responsible for leading and advancing Operational Review, a key element of Quality Governance model
  • Establish KPIs to drive behaviors within External Operations
  • Collaborate with cross functional Quality (Inspection Management, Compliance, International) and CDMO management to ensure pre-approval inspection and commercial readiness activities at the CDMOs
  • Adjudicate on compliance discussions and negotiate any required corrective actions
  • Create and foster a culture of collaboration and engagement for advancing quality outcomes and operational excellence
  • Lead team members, support development of organizational capabilities and talent development
  • Business travel up to 15% of time
Desired Qualifications
  • In-depth global health regulatory agency knowledge and experience across GxP life cycle in small molecules, devices and combination products preferred
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's partnership with Orna enhances its gene therapy capabilities.
  • Increased investments indicate strong investor confidence in Vertex's growth potential.
  • Vertex's global expansion includes a patient assistance program for Trikafta in South Africa.

What critics are saying

  • Vertex is under investigation for potential securities law violations.
  • Mixed Phase II results for suzetrigine may delay its development.
  • The $1.07 billion Orna partnership could strain resources if unsuccessful.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic biotech partnerships.
  • Vertex's innovative gene-editing therapies target sickle cell disease and beta thalassemia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

MarketBeat
Feb 14th, 2025
JSF Financial LLC Invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

JSF Financial LLC invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

MarketBeat
Jan 17th, 2025
Channel Wealth LLC Invests $716,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Channel Wealth LLC invests $716,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Zenopa
Jan 8th, 2025
Vertex and Orna Partner for Innovative Gene Therapy Solutions

In a significant advancement for the biopharma industry, Vertex Pharmaceuticals has announced a partnership with Orna Therapeutics to develop cutting-edge in vivo gene editing therapies targeting sickle cell disease and beta thalassaemia.

Pipeline Review
Jan 8th, 2025
Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

We look forward to partnering with Vertex to develop transformative therapies for SCD and TDT, while simultaneously advancing our lead panCAR(TM) pipeline programs in autoimmune and oncology.

Precision Medicine Online
Jan 7th, 2025
Vertex Gains Rights to Orna Therapeutics' Drug Delivery Tech in $1.07B Deal

NEW YORK - Orna Therapeutics on Tuesday said it has inked a deal with Vertex Pharmaceuticals valued at more than $1.07 billion, in which Vertex will use its drug delivery technology to develop new gene-editing treatments for patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).